PHILADELPHIA--(BUSINESS WIRE)--April 25, 2006--Hemispherx Biopharma, Inc. (AMEX: HEB - News) today announced that it has retained a team of scientists and executives with unique experience in immunology, pharma manufacturing, and regulatory compliance to help the Company prepare for the filing of a new drug application (NDA) for the experimental immunostimulant Ampligen®, developed for the potential treatment of Chronic Fatigue Syndrome (CFS). The management and R&D expansion comes just as the federal Centers for Disease Control and Prevention has unveiled critical research that strengthens the belief that cases of CFS share common factors of hormonal and immune system dysregulation.
